Contract Pharmaceutical Fermentation Services to Grow at nearly 5.9% CAGR through 2026: Fact.MR

The research claims that fermentation services are working with pharmaceutical businesses to increase the penetration of advanced biotechnology, which is leading to growth opportunities. According to Fact.MR research, the rise of contract pharmaceutical fermentation services is being driven by the commercialisation of drugs through organisations that provide contract manufacturing services.

Additionally, the rising incidence of a variety of ailments like cancer, diabetes, cardiovascular diseases, rheumatoid arthritis, haemophilia, and others is driving up need for quick medication development, supporting the market's expansion.

"Leading players are focusing on luring the pharmaceutical companies by integrating advanced biotechnology and investing in research and development activities in diverse applications," claims the Fact.MR analyst.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=1517?AS 

Key Takeaways

• Contract pharmaceutical fermentation services to exceed US$ 4 Bn by 2026
• North America to dominate the market backed by high presence of pharmaceutical industries 
• By products, biotherapeutics to lead the market, followed by vaccines
• Biotechnology companies expected to emerge as a potential end-user
• Peptides and plasmids to growth to be sluggish through 2021

Prominent Drivers

• Rising demand for biosimilar and biologic manufacturing to provide growth opportunities for manufacturers, bolstering the growth
• Diverse application of Contract Pharmaceutical Fermentation Services procedures in developing time-efficient drug development to create growth prospects
• Amid surging production, pharmaceutical companies collaborating with contract pharmaceutical fermentation services to foster the sales

Competitive Landscape

Key players operating in contract pharmaceutical fermentation services market include AbbVie, Inc., Aumgene Biosciences, EKF Diagnostics-Stanbio, Boehringer Ingelheim International GmbH, Biocon, AMRI, Pfizer, Lonza, CordenPharma International, and Fujifilm Holdings Corporation.

In March 2021, AbbVie Inc., announced the extension of review of supplemental new drug application of Upadacitinib for the treatment of adults with active psoriatic arthritis. The research and development-based biopharmaceutical company announced that the FDA has extended the review period and are expected to initiate the research on other immune-meditated diseases.

Likewise, another leading player, Boehringer Ingelheim International GmbH and the Lieber Institute for Brain Development announced a collaboration and new research focused on development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia, advancing the revenues.

Workflow Optimization

The Fact.MR report on contract pharmaceutical fermentation services offers a comprehensive taxonomy of the contract pharmaceutical fermentation services market on the basis of contract pharmaceutical fermentation service type, platform, product type, and end user of contract pharmaceutical fermentation services.

On the basis of service type, the global contract pharmaceutical fermentation services market has been segmented into development services and commercial services. On the basis of platform, the global contract pharmaceutical fermentation services market has been segmented into bacterial and fungal/yeast.

Based on product type, the global contract pharmaceutical fermentation services market has been segmented into bio-therapeutics, enzymes, peptides, plasmids, cytokines & growth factors, vaccines, others (fusion proteins, etc.).

By end user, the global contract pharmaceutical fermentation services market has been segmented into pharmaceutical companies, biotechnology companies, animal health companies, and academic & research institutes. Based on region, the contract pharmaceutical fermentation services market has been bifurcated into North America, Latin America, Europe, and Asia Pacific excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).

More Insights on the Contract Pharmaceutical Fermentation Services Market

In its latest report, Fact.MR offers unbiased analysis of the global Contract Pharmaceutical Fermentation Services market. The report divulges essential insights on Contract Pharmaceutical Fermentation Services market on the basis of platform (bacterial and fungal/yeast), service type (development services and commercial services), product type (biotherapeutics, enzymes, peptides, plasmids, cytokines & growth factors, vaccines and others), end-user (pharmaceutical companies, biotechnology companies, animal health companies, and animal health companies institutes), and regions (North America, Latin America, Europe, Japan, APEJ, and Middle East and Africa)

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=1517?AS